Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follitropin alfa - Merck Serono

Drug Profile

Follitropin alfa - Merck Serono

Alternative Names: Follitropin-alpha; GONAL-f; GONAL-f RFF Redi-ject; Gonalef; Recombinant human follicle-stimulating hormone - Merck Serono; recombinant human follicle-stimulating hormone - Serono; rh-FSH; rhFSH - Merck Serono; rhFSH - Serono; SJ-0021

Latest Information Update: 16 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono; Nippon Shinyaku
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Male infertility
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility; Male infertility

Most Recent Events

  • 13 Nov 2017 The US FDA approves follitropin alfa injection prefilled pen for treatment of Infertility in USA
  • 01 Jul 2015 Follitropin alfa licensed to Nippon Shinyaku in Japan for Male infertility and Female infertility
  • 16 Jan 2014 Phase-III clinical trials in Female infertility (combination therapy) in Finland, Germany, Hungary, Latvia and the United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top